Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
loteprednol etabonate, 0.5% · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Loteprednol Etabonate TID | EXPERIMENTAL | loteprednol etabonate ophthalmic suspension, 0.5%, TID |
| Loteprednol Etabonate QID | EXPERIMENTAL | loteprednol etabonate ophthalmic suspension, 0.5%, QID |
| Vehicle | PLACEBO_COMPARATOR | vehicle of loteprednol etabonate |
| Name | Type | Description |
|---|---|---|
| loteprednol etabonate ophthalmic suspension, 0.5% | DRUG | TID |
| vehicle of loteprednol etabonate | DRUG | TID or BID according to the randomization |
Inclusion Criteria: * at least 18 years of age or older * able and willing to follow instructions, including participation in study assessments and able be present for the required study visits for the duration of the study * If female and of childbearing potential, were not pregnant, nursing, or p...
Loteprednol Etabonate is a small molecule being developed for ocular conditions including cataract, dry eye, inflammation, ocular inflammation, and seasonal allergic conjunctivitis. It is an investigational drug in clinical development, studied in completed trials for these indications.
Loteprednol Etabonate is developed by Bausch + Lomb Corporation, traded on the New York Stock Exchange under the ticker BLCO. The company is conducting clinical research on this ophthalmic drug candidate.
Loteprednol Etabonate is in Phase 1 development, though its completed clinical trials include Phase 2 and Phase 3 studies. It is an investigational drug, not yet approved, and remains in clinical development for ocular indications.
Loteprednol Etabonate has completed three trials: NCT00560638 for dry eye, NCT00699153 for ocular inflammation after cataract surgery, and NCT01435460 for seasonal allergic conjunctivitis. A fourth trial, NCT01475643, studied it for intraocular inflammation following cataract surgery in children.
Loteprednol Etabonate is a corticosteroid, but its specific molecular target is not disclosed in available data. It is being studied for its anti-inflammatory effects in ocular conditions such as inflammation and allergic conjunctivitis.